This special series focuses on important community issues, innovative solutions to societal challenges, and people and non-profit groups making an impact through technology. by Amy Rolph on Sep 15, ...
The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing ...